Translational Research

1. Safety And Efficacy Advancements In Genome Editing 11/9/2024

   Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics shares his take on the high frequency of productive edits for base editing. In addition, Celularity’s Chairman, Founder, and CEO, Dr. Robert Hariri, shares how he sees non-viral gene delivery methods potentially enhancing cell therapy platforms.

2. Plasmid Complexity And The Push For Stronger CGT Material Control 4/1/2026

   In this segment of Cell & Gene Live, Anthony Blaszczyk, Ph.D., Senior Scientist at the U.S. Pharmacopeia, and Basak Clements, Ph.D., Founder and Senior Advisor at biomatria, were joined by Cell & Gene Chief Editor Erin Harris to discuss why complex materials such as plasmid DNA are critical yet challenging in cell and gene therapy because small variations (e.g., sequence or structure) can significantly impact the final product, and current analytical tools often struggle to fully characterize them.

3. Audience Q&A | Inside The Most Promising Non-Viral Approaches To Genetic Engineering 11/9/2024

   Expert panelists, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics, provided detailed responses to our audience questions on electroporation, CRISPR, delivery technologies beyond LNPs, CAR T-cell therapy, and more.

4. Early-Phase Whole-Body PK 4/21/2025

   Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.

5. A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol 1/23/2025

   Learn about a novel LCMS assay for 4β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.

6. Mitigate Clinical Risk In Cell Therapy Development With A GMP Compliant Process 4/21/2025

   Help shape the future of medicine by building better, safer cell therapies. See how expertise in scalable, GMP-compliant cell engineering can effectively mitigate clinical development risks.

7. Can You Run Crude Samples Using An SPR Instrument? 2/17/2022

   We explore a common misconception and provide examples of complex material being used in an SPR system.

8. LC/MS Method For Measurement In Human Plasma 2/17/2025

   According to the researchers, this plasma-based measurement has the potential to serve as a critical pharmacodynamic biomarker, facilitating the assessment of novel therapeutic approaches.

9. Elucidating The Role Of IL-18 In NSCLC Integrated Analysis 1/23/2025

   Hear how imaging mass cytometry, CyTOF, and single-cell sequencing unlock the secrets of the tumor microenvironment. Discover new insights into IL-18 and its impact on non-small cell lung cancer.

10. Is Evaporation Important For Optical Biosensors? 2/17/2022

    If your sample is open to evaporation effects causing your concentration to change, will your data, and potentially your conclusions, be unreliable?